Tiziana Life Sciences Ltd. has announced the publication of a new clinical study in the Journal of Clinical Nuclear Medicine, showcasing promising results for their lead development candidate, intranasal foralumab, in treating moderate Alzheimer's disease. The study demonstrated that intranasal administration of foralumab significantly reduced microglial activation in a 78-year-old patient with moderate Alzheimer's, treated under an FDA expanded access program. This breakthrough highlights a potential new treatment avenue for neurological disorders. Tiziana's CEO, Ivor Elrifi, emphasized the unmet need for disease-modifying therapies for moderate Alzheimer's and announced the initiation of a phase-2a study for mild Alzheimer's. Foralumab, a fully human anti-CD3 monoclonal antibody, aims to reduce central nervous system inflammation by modulating T cell function, and has shown potential in multiple sclerosis and other neuroinflammatory conditions.